Chemotherapy Response and Recurrence-Free Survival in Neoadjuvant Breast Cancer Depends on Biomarker Profiles: Results From the I-Spy 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-011-1895-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-Spy 1 TRIAL—CALGB 150007/150012, ACRIN 6657

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

Predictors of Recurrence in Breast Cancer Patients With a Pathologic Complete Response After Neoadjuvant Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2010English

Neoadjuvant Chemotherapy in Breast Cancer

English

KIBRA; A Novel Biomarker Predicting Recurrence Free Survival of Breast Cancer Patients Receiving Adjuvant Therapy

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Neoadjuvant Chemotherapy: Role in Breast Cancer

2013English

Germline BRCA, Chemotherapy Response Scores, and Survival in the Neoadjuvant Treatment of Ovarian Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Comedications Influence Immune Infiltration and Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer

OncoImmunology
OncologyAllergyImmunology
2019English

Multiagent Neoadjuvant Chemotherapy and Tumor Response Are Associated With Improved Survival in Pancreatic Cancer

HPB
HepatologyGastroenterology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy